Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase 2 adicionando os medicamentos tazemetostat ou zanubrutinibe ao tratamento usual para pessoas com linfoma de células B grandes que retornaram ou não responderam ao tratamento anterior

16 de novembro de 2026 atualizado por: SWOG Cancer Research Network

Estudo randomizado de fase II da adição de agentes terapêuticos direcionados à terapia baseada em tafasitamabe em pacientes não elegíveis para transplante com linfoma de grandes células B recidivante/refratário

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose of tafasitamab + lenalidomide + tazemetostat AND of tafasitamab + lenalidomide + zanubrutinib. (Safety Run-in) II. To compare progression-free survival (PFS) of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) treated with tafasitamab + lenalidomide + tazemetostat vs control (tafasitamab + lenalidomide) AND treated with tafasitamab + lenalidomide + zanubrutinib versus (vs) control. (Randomized Phase II Study)

SECONDARY OBJECTIVES:

I. To estimate the hazard ratio for PFS for control vs. tafasitamab + lenalidomide + tazemetostat in germinal center B-cell (GCB) and non-GCB (activated B-cell [ABC]/unclassified) subsets.

II. To estimate the hazard ratio for PFS for control vs. tafasitamab + lenalidomide + zanubrutinib in GCB and non-GCB (ABC/unclassified) subsets.

III. To estimate progression-free survival (PFS), overall response rate (ORR), complete response rate (CR), partial response rate (PR), duration of response (DOR), event-free survival (EFS), overall survival (OS), in GCB and non-GCB LBCL for each treatment.

IV. To evaluate adverse events within each treatment arm.

OTHER OBJECTIVES:

I. To explore PFS within subgroups defined by molecular profile (e.g., MCD, BN2, N1 and EZB) and genetic subtypes.

II. To explore PFS in the tafasitamab-lenalidomide control arm vs that in matched historical control from L-MIND and realMIND studies.

III. To assess frailty (Cumulative Illness Rating Scale [CIRS] and Timed Get Up and Go [TUG]) and its correlation with outcome.

PRIMARY PATIENT-REPORTED OUTCOMES OBJECTIVE:

I. To compare patient-reported lymphoma-specific symptoms as measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Trial Outcome Index sub-scale at 3 months after randomization between the control arm and each experimental arm (Arm 1 versus Arm 2 and Arm 3 versus Arm 2).

SECONDARY PATIENT-REPORTED OUTCOMES OBJECTIVE:

I. To compare participant-reported toxicity (treatment side effect) symptoms using selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items between experimental vs control arms.

EXPLORATORY PATIENT-REPORTED OUTCOMES OBJECTIVES:

I. To compare patient-reported quality of life using the FACT-General (G) subscale score and the FACT-Lym total score at 3 months after randomization between the control arm and each experimental arm.

II. To compare quality of life over time between treatment arms from baseline to 12 months after randomization as measured by the FACT-Lym trial outcome index (TOI), FACT-G, and FACT-Lym total score using longitudinal analysis.

BANKING OBJECTIVE:

I. To bank specimens for future correlative studies.

OUTLINE: This is a dose-escalation study of tazemetostat and zanubrutinib.

PART I (SAFETY RUN-IN): Patients are assigned to 1 of 2 arms per treating investigator's choice.

ARM I: Patients receive tafasitamab intravenously (IV), lenalidomide orally (PO), and tazemetostat PO on study. Patients also undergo positron emission tomography/computed tomography (PET/CT) and CT or magnetic resonance imaging (MRI) scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

ARM III: Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

PART II: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

ARM II: Patients receive tafasitamab IV and lenalidomide PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

ARM III: Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

Tipo de estudo

Intervencional

Inscrição (Estimado)

227

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Katarina Gasic
  • Número de telefone: 210-677-8808
  • E-mail: kgasic@swog.org

Estude backup de contato

  • Nome: Crystal Miwa
  • Número de telefone: 210-677-8808
  • E-mail: cmiwa@swog.org

Locais de estudo

    • Arizona
      • Tucson, Arizona, Estados Unidos, 85719
        • Recrutamento
        • Banner University Medical Center - Tucson
        • Contato:
        • Investigador principal:
          • Krishna Rekha Moturi
      • Tucson, Arizona, Estados Unidos, 85719
        • Recrutamento
        • University of Arizona Cancer Center-North Campus
        • Contato:
        • Investigador principal:
          • Krishna Rekha Moturi
    • California
      • Beverly Hills, California, Estados Unidos, 90211
      • Duarte, California, Estados Unidos, 91010
        • Recrutamento
        • City of Hope Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Alexey V. Danilov
      • Huntington Beach, California, Estados Unidos, 92648
        • Recrutamento
        • City of Hope Seacliff
        • Investigador principal:
          • Alexey V. Danilov
        • Contato:
          • Site Public Contact
          • Número de telefone: 626-256-4673
      • Lancaster, California, Estados Unidos, 93534
        • Recrutamento
        • City of Hope Antelope Valley
        • Contato:
        • Investigador principal:
          • Alexey V. Danilov
      • Long Beach, California, Estados Unidos, 90813
        • Recrutamento
        • City of Hope at Long Beach Elm
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-467-3411
        • Investigador principal:
          • Alexey V. Danilov
      • Los Angeles, California, Estados Unidos, 90048
        • Recrutamento
        • Cedars Sinai Medical Center
        • Investigador principal:
          • Akil A. Merchant
        • Contato:
          • Site Public Contact
          • Número de telefone: 310-423-8965
      • Newport Beach, California, Estados Unidos, 92660
        • Recrutamento
        • City of Hope Newport Beach
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-467-3411
        • Investigador principal:
          • Alexey V. Danilov
      • South Pasadena, California, Estados Unidos, 91030
        • Recrutamento
        • City of Hope South Pasadena
        • Contato:
        • Investigador principal:
          • Alexey V. Danilov
      • Torrance, California, Estados Unidos, 90503
        • Recrutamento
        • City of Hope South Bay
        • Contato:
          • Site Public Contact
          • Número de telefone: 877-467-3411
        • Investigador principal:
          • Alexey V. Danilov
      • Upland, California, Estados Unidos, 91786
        • Recrutamento
        • City of Hope Upland
        • Contato:
        • Investigador principal:
          • Alexey V. Danilov
    • Florida
      • Fort Lauderdale, Florida, Estados Unidos, 33308
        • Recrutamento
        • Holy Cross Hospital
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Miami Beach, Florida, Estados Unidos, 33140
        • Suspenso
        • Mount Sinai Medical Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago Comprehensive Cancer Center
        • Contato:
        • Investigador principal:
          • Justin P. Kline
      • Chicago, Illinois, Estados Unidos, 60612
        • Recrutamento
        • University of Illinois
        • Contato:
          • Site Public Contact
          • Número de telefone: 312-355-3046
        • Investigador principal:
          • Paul G. Rubinstein
      • Danville, Illinois, Estados Unidos, 61832
        • Recrutamento
        • Carle at The Riverfront
        • Investigador principal:
          • Suparna Mantha
        • Contato:
      • Effingham, Illinois, Estados Unidos, 62401
        • Recrutamento
        • Carle Physician Group-Effingham
        • Investigador principal:
          • Suparna Mantha
        • Contato:
      • Mattoon, Illinois, Estados Unidos, 61938
        • Recrutamento
        • Carle Physician Group-Mattoon/Charleston
        • Investigador principal:
          • Suparna Mantha
        • Contato:
      • New Lenox, Illinois, Estados Unidos, 60451
        • Recrutamento
        • UC Comprehensive Cancer Center at Silver Cross
        • Contato:
        • Investigador principal:
          • Justin P. Kline
      • Orland Park, Illinois, Estados Unidos, 60462
        • Recrutamento
        • University of Chicago Medicine-Orland Park
        • Contato:
        • Investigador principal:
          • Justin P. Kline
      • Shiloh, Illinois, Estados Unidos, 62269
        • Recrutamento
        • Memorial Hospital East
        • Contato:
        • Investigador principal:
          • Nancy L. Bartlett
      • Urbana, Illinois, Estados Unidos, 61801
        • Recrutamento
        • Carle Cancer Center
        • Investigador principal:
          • Suparna Mantha
        • Contato:
    • Indiana
      • Crown Point, Indiana, Estados Unidos, 46307
        • Recrutamento
        • Northwest Cancer Center - Main Campus
        • Investigador principal:
          • Suparna Mantha
        • Contato:
          • Site Public Contact
          • Número de telefone: 219-310-2550
      • Dyer, Indiana, Estados Unidos, 46311
        • Recrutamento
        • Northwest Oncology LLC
        • Investigador principal:
          • Suparna Mantha
        • Contato:
          • Site Public Contact
          • Número de telefone: 219-924-8178
      • Hobart, Indiana, Estados Unidos, 46342
        • Recrutamento
        • Northwest Cancer Center - Hobart
        • Investigador principal:
          • Suparna Mantha
        • Contato:
          • Site Public Contact
          • Número de telefone: 219-947-1795
      • Hobart, Indiana, Estados Unidos, 46342
        • Recrutamento
        • Saint Mary Medical Center
        • Investigador principal:
          • Suparna Mantha
        • Contato:
      • Indianapolis, Indiana, Estados Unidos, 46312
        • Recrutamento
        • Saint Catherine Hospital
        • Investigador principal:
          • Suparna Mantha
        • Contato:
      • Munster, Indiana, Estados Unidos, 46321
        • Recrutamento
        • The Community Hospital
        • Investigador principal:
          • Suparna Mantha
        • Contato:
          • Site Public Contact
          • Número de telefone: 219-836-3349
      • Munster, Indiana, Estados Unidos, 46321
        • Recrutamento
        • Women's Diagnostic Center - Munster
        • Investigador principal:
          • Suparna Mantha
        • Contato:
      • Valparaiso, Indiana, Estados Unidos, 46383
        • Recrutamento
        • Northwest Cancer Center - Valparaiso
        • Investigador principal:
          • Suparna Mantha
        • Contato:
    • Iowa
      • Ankeny, Iowa, Estados Unidos, 50023
        • Suspenso
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Recrutamento
        • Mercy Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 319-365-4673
        • Investigador principal:
          • Deborah W. Wilbur
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Recrutamento
        • Oncology Associates at Mercy Medical Center
        • Investigador principal:
          • Deborah W. Wilbur
        • Contato:
          • Site Public Contact
          • Número de telefone: 319-363-2690
      • Clive, Iowa, Estados Unidos, 50325
        • Suspenso
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, Estados Unidos, 50314
        • Recrutamento
        • Mercy Medical Center - Des Moines
        • Investigador principal:
          • Richard L. Deming
        • Contato:
      • Des Moines, Iowa, Estados Unidos, 50314
        • Suspenso
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • Recrutamento
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Brighton, Michigan, Estados Unidos, 48114
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Brighton, Michigan, Estados Unidos, 48114
        • Recrutamento
        • Trinity Health Medical Center - Brighton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Canton, Michigan, Estados Unidos, 48188
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Canton, Michigan, Estados Unidos, 48188
        • Recrutamento
        • Trinity Health Medical Center - Canton
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Chelsea, Michigan, Estados Unidos, 48118
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Chelsea, Michigan, Estados Unidos, 48118
      • Flint, Michigan, Estados Unidos, 48503
        • Recrutamento
        • Genesys Hurley Cancer Institute
        • Contato:
          • Site Public Contact
          • Número de telefone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Investigador principal:
          • Tareq Al baghdadi
      • Flint, Michigan, Estados Unidos, 48503
        • Recrutamento
        • Hurley Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Investigador principal:
          • Tareq Al baghdadi
      • Flint, Michigan, Estados Unidos, 48503
        • Suspenso
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Estados Unidos, 48503
        • Recrutamento
        • Cancer Hematology Centers - Flint
        • Contato:
          • Site Public Contact
          • Número de telefone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Investigador principal:
          • Tareq Al baghdadi
      • Lansing, Michigan, Estados Unidos, 48912
        • Recrutamento
        • University of Michigan Health - Sparrow Lansing
        • Investigador principal:
          • Tareq Al baghdadi
        • Contato:
      • Livonia, Michigan, Estados Unidos, 48154
        • Recrutamento
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Pontiac, Michigan, Estados Unidos, 48341
        • Recrutamento
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
      • Ypsilanti, Michigan, Estados Unidos, 48106
      • Ypsilanti, Michigan, Estados Unidos, 48197
        • Recrutamento
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contato:
        • Investigador principal:
          • Tareq Al baghdadi
    • Minnesota
      • Deer River, Minnesota, Estados Unidos, 56636
        • Recrutamento
        • Essentia Health - Deer River Clinic
        • Contato:
        • Investigador principal:
          • Bret E. Friday
      • Duluth, Minnesota, Estados Unidos, 55805
        • Recrutamento
        • Essentia Health Cancer Center
        • Contato:
        • Investigador principal:
          • Bret E. Friday
      • Hibbing, Minnesota, Estados Unidos, 55746
        • Recrutamento
        • Essentia Health Hibbing Clinic
        • Investigador principal:
          • Bret E. Friday
        • Contato:
          • Site Public Contact
          • Número de telefone: 218-786-3308
      • Sandstone, Minnesota, Estados Unidos, 55072
        • Recrutamento
        • Essentia Health Sandstone
        • Contato:
        • Investigador principal:
          • Bret E. Friday
      • Virginia, Minnesota, Estados Unidos, 55792
        • Recrutamento
        • Essentia Health Virginia Clinic
        • Contato:
        • Investigador principal:
          • Bret E. Friday
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39216
        • Recrutamento
        • University of Mississippi Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 601-815-6700
        • Investigador principal:
          • Carrie K. Wynn
    • Missouri
      • City of Saint Peters, Missouri, Estados Unidos, 63376
        • Recrutamento
        • Siteman Cancer Center at Saint Peters Hospital
        • Investigador principal:
          • Nancy L. Bartlett
        • Contato:
      • Creve Coeur, Missouri, Estados Unidos, 63141
        • Recrutamento
        • Siteman Cancer Center at West County Hospital
        • Investigador principal:
          • Nancy L. Bartlett
        • Contato:
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Washington University School of Medicine
        • Investigador principal:
          • Nancy L. Bartlett
        • Contato:
      • St Louis, Missouri, Estados Unidos, 63129
        • Recrutamento
        • Siteman Cancer Center-South County
        • Investigador principal:
          • Nancy L. Bartlett
        • Contato:
      • St Louis, Missouri, Estados Unidos, 63136
        • Recrutamento
        • Siteman Cancer Center at Christian Hospital
        • Investigador principal:
          • Nancy L. Bartlett
        • Contato:
    • New York
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Investigador principal:
          • Jennifer E. Amengual
        • Contato:
      • Rochester, New York, Estados Unidos, 14642
        • Recrutamento
        • University of Rochester
        • Contato:
          • Site Public Contact
          • Número de telefone: 585-275-5830
        • Investigador principal:
          • Patrick M. Reagan
      • Webster, New York, Estados Unidos, 14580
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Recrutamento
        • University of Oklahoma Health Sciences Center
        • Contato:
        • Investigador principal:
          • Taha Al-Juhaishi
    • Oregon
      • Newberg, Oregon, Estados Unidos, 97132
        • Recrutamento
        • Providence Newberg Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Oregon City, Oregon, Estados Unidos, 97045
        • Recrutamento
        • Providence Willamette Falls Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Portland, Oregon, Estados Unidos, 97213
        • Recrutamento
        • Providence Portland Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
      • Portland, Oregon, Estados Unidos, 97225
        • Recrutamento
        • Providence Saint Vincent Medical Center
        • Contato:
        • Investigador principal:
          • Charles W. Drescher
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Recrutamento
        • Medical University of South Carolina
        • Contato:
        • Investigador principal:
          • Brian T. Hess
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 713-798-1354
          • E-mail: burton@bcm.edu
        • Investigador principal:
          • Akiva Diamond
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Ben Taub General Hospital
        • Contato:
          • Site Public Contact
          • Número de telefone: 713-873-2000
        • Investigador principal:
          • Akiva Diamond
      • San Antonio, Texas, Estados Unidos, 78229
        • Recrutamento
        • University of Texas Health Science Center at San Antonio
        • Contato:
        • Investigador principal:
          • Adolfo E. Diaz Duque
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Recrutamento
        • Huntsman Cancer Institute/University of Utah
        • Contato:
        • Investigador principal:
          • Allison Bock
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23235
        • Recrutamento
        • VCU Massey Cancer Center at Stony Point
        • Investigador principal:
          • Victor Y. Yazbeck
        • Contato:
      • Richmond, Virginia, Estados Unidos, 23298
        • Recrutamento
        • VCU Massey Comprehensive Cancer Center
        • Investigador principal:
          • Victor Y. Yazbeck
        • Contato:
    • Wisconsin
      • Appleton, Wisconsin, Estados Unidos, 54911
        • Recrutamento
        • ThedaCare Regional Cancer Center
        • Contato:
        • Investigador principal:
          • Yazhini Vallatharasu
      • Ashland, Wisconsin, Estados Unidos, 54806
        • Recrutamento
        • Duluth Clinic Ashland
        • Contato:
        • Investigador principal:
          • Bret E. Friday
      • Burlington, Wisconsin, Estados Unidos, 53105
        • Recrutamento
        • Aurora Cancer Care-Southern Lakes VLCC
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Eau Claire, Wisconsin, Estados Unidos, 54701
      • Germantown, Wisconsin, Estados Unidos, 53022
        • Recrutamento
        • Aurora Health Care Germantown Health Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Grafton, Wisconsin, Estados Unidos, 53024
        • Recrutamento
        • Aurora Cancer Care-Grafton
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Green Bay, Wisconsin, Estados Unidos, 54311
        • Recrutamento
        • Aurora BayCare Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Kenosha, Wisconsin, Estados Unidos, 53142
        • Recrutamento
        • Aurora Cancer Care-Kenosha South
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Recrutamento
        • Gundersen Lutheran Medical Center
        • Contato:
        • Investigador principal:
          • David E. Marinier
      • Marinette, Wisconsin, Estados Unidos, 54143
        • Recrutamento
        • Aurora Bay Area Medical Group-Marinette
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Marshfield, Wisconsin, Estados Unidos, 54449
      • Milwaukee, Wisconsin, Estados Unidos, 53209
        • Recrutamento
        • Aurora Cancer Care-Milwaukee
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Recrutamento
        • Aurora Saint Luke's Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Milwaukee, Wisconsin, Estados Unidos, 53233
        • Recrutamento
        • Aurora Sinai Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Minocqua, Wisconsin, Estados Unidos, 54548
      • Oshkosh, Wisconsin, Estados Unidos, 54904
        • Recrutamento
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Racine, Wisconsin, Estados Unidos, 53406
        • Recrutamento
        • Aurora Cancer Care-Racine
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Rice Lake, Wisconsin, Estados Unidos, 54868
      • Sheboygan, Wisconsin, Estados Unidos, 53081
        • Recrutamento
        • Vince Lombardi Cancer Clinic-Sheboygan
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Stevens Point, Wisconsin, Estados Unidos, 54482
      • Summit, Wisconsin, Estados Unidos, 53066
        • Recrutamento
        • Aurora Medical Center in Summit
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Two Rivers, Wisconsin, Estados Unidos, 54241
        • Recrutamento
        • Vince Lombardi Cancer Clinic-Two Rivers
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Wauwatosa, Wisconsin, Estados Unidos, 53226
        • Recrutamento
        • Aurora Cancer Care-Milwaukee West
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • West Allis, Wisconsin, Estados Unidos, 53227
        • Recrutamento
        • Aurora West Allis Medical Center
        • Contato:
          • Site Public Contact
          • Número de telefone: 414-302-2304
          • E-mail: ncorp@aurora.org
        • Investigador principal:
          • Thomas J. Saphner
      • Weston, Wisconsin, Estados Unidos, 54476

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participants must have:

    • Histologically confirmed relapsed/refractory LBCL as outlined by the World Health Organization (WHO) guidelines
    • Follicular lymphoma, grade 3B
    • Transformed lymphoma
    • High grade B-cell lymphoma with or without MYC, BCL2 and/or BCL6 rearrangements
  • Participants must have staging imaging performed within 28 days prior to registration, as follows. Positron emission tomography (PET)-computed tomography (CT) baseline scans are strongly preferred; diagnostic quality magnetic resonance imaging (MRI), contrast-enhanced CT, or contrast-enhanced MRI scans are also acceptable if PET-CT is not feasible at baseline. Note: PET-CT will be required at end of treatment (EOT) and progression for response assessment. All measurable lesions (longest diameter >= 1.5 cm) must be assessed within 28 days prior to registration. Tests to assess non-measurable disease must be performed within 28 days prior to registration. All disease must be documented on the Baseline Tumor Assessment Form.

  • Participants must have cell of origin (COO) determination of germinal center (GC)(GCB or non-GC GCB) of LBCL based on Hans immunohistochemistry algorithm (CD10, BCL6, MUM1) as noted on pathology report.

  • Participants must have had 1-5 prior systemic treatment regimens including one systemic multiagent regimen for aggressive lymphoma

  • Participants who have received prior systemic therapy must have completed their last treatment prior to registration. Participants must have recovered from previous therapy

  • Steroid use for the control of non-Hodgkin lymphoma symptoms is allowable, but must be discontinued prior to Cycle 1, Day 1

  • Participant must be >= 18 years old

  • Participant must have Zubrod Performance Status of 0-3

  • Participant must have a complete medical history and physical exam within 28 days prior to registration

  • Absolute neutrophil count >= 1.0 x 10^3/uL (within 28 days prior to registration)

    • If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Absolute neutrophil count (ANC) >= 0.75 x 10^3/uL
  • Platelets >= 75 x 10^3/uL (within 28 days prior to registration)

    • If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Platelets >= 50 x 10^3/uL
  • Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (IULN), alanine aminotransferase (ALT) =< 3 x IULN (within 28 days prior to registration) unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver.

    • Participants with lymphomatous involvement of the liver must have AST =< 5 x IULN, ALT =< 5 x IULN
  • Total bilirubin =< 1.5 x IULN (within 28 days prior to registration) unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver.

    • Participants with lymphomatous involvement of the liver must have total bilirubin =< 5 x IULN
  • Participants must have a calculated creatinine clearance >= 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration

  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Participants must have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia

  • Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration

  • Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained within the last year and received suppressive therapy

  • Participants with a history of hepatitis C virus (HCV) infection must have an undetectable viral load. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 28 days prior to registration

  • Participants must be able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels

  • Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System

  • Participants who can complete the FACT-Lym and PRO-CTCAE forms in English or Spanish must agree to participate in the patient-reported outcome study

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.

    • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and central institutional review board (CIRB) regulations.

Exclusion Criteria:

  • Participants must not have active lymphomatous involvement of the central nervous system (CNS) because the treatments used in this study are not effective to sufficiently penetrate the blood brain barrier

  • Participants must not have known abnormalities associated with myelodysplastic syndrome (MDS) (e.g., del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g., JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing. Testing is not required for eligibility determination

  • Participants must not have a known prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute leukemia (T-ALL). Testing is not required for eligibility determination

  • Participants must not be a candidate based on investigator assessment to receive autologous stem cell transplant (ASCT) or must have declined ASCT. Participants who had disease progression after stem cell transplant or cellular therapy (such as chimeric antigen receptor (CAR) T-cell) are eligible

  • Participants must not have received prior treatment with tafasitamab and/or lenalidomide

  • Participants must not have had prior BTK inhibitor or tazemetostat

  • Participants must not have any known allergy or reaction to any component of tafasitamab, lenalidomide, tazemetostat or zanubrutinib

  • Participants must not be receiving direct vitamin K inhibitors or strong or moderate CYP3A inhibitors or inducers at the date of registration

    • Notes: Because the list of these agents is constantly changing, it is important to regularly consult a frequently updated medical reference
  • Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen

  • Participants must not be pregnant or nursing and must follow the guidelines according to the lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program. The effects of tazemetostat, zanubrutinib, lenalidomide and tafasitamab, and the combination of these drugs have not been studied on the developing human fetus are the effects are unknown. Individuals who are of reproductive potential must have agreed to use a highly effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential". In addition to routine contraceptive methods, "acceptable contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)

Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Given PO

Outros nomes:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância magnética (procedimento)

Undergo PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • imagens espectroscópicas de ressonância magnética de prótons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given PO

Outros nomes:
  • EPZ-6438
  • E7438
  • EPZ6438

Given IV

Outros nomes:
  • MOR208
  • Monjuvi
  • MOR-00208
  • MOR00208
  • Tafasitamab-cxix
  • XmAb5574
  • Imunoglobulina, Anti-(Antígeno Cd19 Humano) (Cadeia Pesada Monoclonal Human-mus musculus MOR00208), Dissulfeto com Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer

Undergo PET/CT and CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)

Undergo optional collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras
Experimental: Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)

Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Given PO

Outros nomes:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância magnética (procedimento)

Ancillary studies

Undergo PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • imagens espectroscópicas de ressonância magnética de prótons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • MOR208
  • Monjuvi
  • MOR-00208
  • MOR00208
  • Tafasitamab-cxix
  • XmAb5574
  • Imunoglobulina, Anti-(Antígeno Cd19 Humano) (Cadeia Pesada Monoclonal Human-mus musculus MOR00208), Dissulfeto com Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer

Undergo PET/CT and CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)

Given PO

Outros nomes:
  • Brukinsa
  • BGB-3111
  • BTK-InhB

Undergo optional collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras
Experimental: Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)

Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Given PO

Outros nomes:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância magnética (procedimento)

Ancillary studies

Undergo PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • imagens espectroscópicas de ressonância magnética de prótons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given PO

Outros nomes:
  • EPZ-6438
  • E7438
  • EPZ6438

Given IV

Outros nomes:
  • MOR208
  • Monjuvi
  • MOR-00208
  • MOR00208
  • Tafasitamab-cxix
  • XmAb5574
  • Imunoglobulina, Anti-(Antígeno Cd19 Humano) (Cadeia Pesada Monoclonal Human-mus musculus MOR00208), Dissulfeto com Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer

Undergo PET/CT and CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)

Undergo optional collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras
Comparador Ativo: Part II, Arm II (tafasitamab, lenalidomide)

Patients receive tafasitamab IV and lenalidomide PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Given PO

Outros nomes:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância magnética (procedimento)

Ancillary studies

Undergo PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • imagens espectroscópicas de ressonância magnética de prótons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • MOR208
  • Monjuvi
  • MOR-00208
  • MOR00208
  • Tafasitamab-cxix
  • XmAb5574
  • Imunoglobulina, Anti-(Antígeno Cd19 Humano) (Cadeia Pesada Monoclonal Human-mus musculus MOR00208), Dissulfeto com Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer

Undergo PET/CT and CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)

Undergo optional collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras
Experimental: Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)

Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.

Ancillary studies

Outros nomes:
  • Avaliação da Qualidade de Vida

Given PO

Outros nomes:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância magnética (procedimento)

Ancillary studies

Undergo PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • imagens espectroscópicas de ressonância magnética de prótons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Given IV

Outros nomes:
  • MOR208
  • Monjuvi
  • MOR-00208
  • MOR00208
  • Tafasitamab-cxix
  • XmAb5574
  • Imunoglobulina, Anti-(Antígeno Cd19 Humano) (Cadeia Pesada Monoclonal Human-mus musculus MOR00208), Dissulfeto com Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer

Undergo PET/CT and CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)

Given PO

Outros nomes:
  • Brukinsa
  • BGB-3111
  • BTK-InhB

Undergo optional collection of blood

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-free survival (PFS)
Prazo: From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years

Will be compared between participants randomized to control Arm 2 (tafasitamab + lenalidomide) versus (vs) experimental Arm 1 (tafasitamab + lenalidomide + tazemetostat), AND control Arm 2 vs experimental Arm 3 (tafasitamab + lenalidomide + zanubrutinib), respectively.

From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
Trial Outcome Index (TOI) score from the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) (Patient Reported Outcome [PRO] Study)
Prazo: Baseline up to 3 months after randomization

Will compare the trial outcome index (TOI) score between each experimental arm (Arm 1 and Arm 3) to the control arm (Arm 2). The TOI score is composed of the Physical Well-Being, Functional Well-Being, and lymphoma-specific subscale scores. The scores range from 0-116, with higher scores indicating a higher quality of life.

Baseline up to 3 months after randomization

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Hazard ratio for PFS in the germinal center B-cell (GCB) subgroup
Prazo: Up to 3 years

Will calculate the 80% confidence interval (CI) for the Cox regression time-to-event estimate of the hazard ratio associated with addition of tazemetostat to tafasitamab+lenalidomide combination (Arm 2 vs Arm 1) in the GCB subgroup. If the confidence interval excludes 1, then 80% CI will be calculated for the non-GCB group.

Up to 3 years
Hazard ratio for PFS in the non-GCB subgroup
Prazo: Up to 3 years

Will calculate the 80% CI for the hazard ratio associated with addition of zanubrutinib to tafasitamab+lenalidomide combination (Arm 2 vs Arm 3) in the non-GCB subgroup. If the confidence interval excludes 1, then 80% CI will be calculated for the GCB group.

Up to 3 years
PFS
Prazo: From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years

Will estimate in GCB and non-GCB large B-cell lymphoma (LBCL) for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
Overall response rate (ORR)
Prazo: Up to 3 years

Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

Up to 3 years
Complete response (CR) rate
Prazo: Up to 3 years

Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

Up to 3 years
Partial response (PR) rate
Prazo: Up to 3 years

Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

Up to 3 years
Duration of response (DOR)
Prazo: From date of first documentation of response to treatment (CR, PR) to date of first documentation of progression, or death due to any cause among patients who achieve a response (CR or PR), assessed up to 3 years

Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

From date of first documentation of response to treatment (CR, PR) to date of first documentation of progression, or death due to any cause among patients who achieve a response (CR or PR), assessed up to 3 years
Event free survival (EFS)
Prazo: From date of randomization to date of first occurrence of EFS event, assessed up to 3 years

Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

From date of randomization to date of first occurrence of EFS event, assessed up to 3 years
Overall survival (OS)
Prazo: From date of randomization to date of death due to any cause, assessed up to 3 years

Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated.

From date of randomization to date of death due to any cause, assessed up to 3 years
Incidence of adverse events
Prazo: Up to 3 years

Will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Eligible participants receiving at least one dose of drug will be included in the assessment of adverse events by treatment arms. The maximum Grade for each toxicity will be recorded for each participant, and frequency tables will be reviewed to determine toxicity patterns. With 60 eligible participants in each arm, any toxicity occurring with at least 5% probability is likely to be seen at least once (95% chance). Toxicity rates in each arm can be estimated to within at least +/- 13% with 95% confidence.

Up to 3 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jennifer E Amengual, SWOG Cancer Research Network

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

26 de setembro de 2023

Conclusão Primária (Estimado)

1 de dezembro de 2029

Conclusão do estudo (Estimado)

1 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

25 de maio de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de maio de 2023

Primeira postagem (Real)

6 de junho de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever